KaydedilenlerDerginizi ekleyin

Dergiler / Journal of Experimental and Clinical Medicine / 2021 / Volume: 38 Issue: 4

Comparison of the efficacy of PSI, CURB-65, CALL and BCRSS in predicting prognosis and mortality in COVID-19 patients

Hatice Şeyma Akça(DEPARTMENT OF FIRST AID AND EMERGENCY)0000-0003-2823-9577
Abdullah Algın(DEPARTMENT OF FIRST AID AND EMERGENCY)0000-0002-9016-9701
Serdar Özdemir(DEPARTMENT OF FIRST AID AND EMERGENCY)0000-0002-6186-6110
Habib Sevimli(DEPARTMENT OF FIRST AID AND EMERGENCY)0000-0003-4475-1669
Kamil Kokulu(DEPARTMENT OF FIRST AID AND EMERGENCY)0000-0002-6132-0898
Serkan Emre Eroğlu(DEPARTMENT OF FIRST AID AND EMERGENCY)0000-0002-3183-3713
Sayfa
—
Yayın Tarihi
2021-10-09
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion Scoring systems, which include comorbidity, vital signs as well as laboratory, imaging findings, will be more effective than other scoring systems in determining the mortality in patients with covid-19.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction This study aimed to determine whether the PSI, CURB-65, CALL and BCRSS had any superiority over each other as a prognostic determinant in patients with COVID-19.
📊
Temel Bulgular & Veri:Material and Method This prospective cohort study included patients over 18 years of age that presented to the emergency department between May 12 and August 12, 2020 and had a positive COVID-19 polymerase chain reaction (PCR) test.
💡
Sonuç & Katkı:Conclusion Scoring systems, which include comorbidity, vital signs as well as laboratory, imaging findings, will be more effective than other scoring systems in determining the mortality in patients with covid-19.
🔬Tür:Research Article
📍Kapsam:2020 Verileri
⚙️Değişkenler:PSI · CURB-65 · CALL

Abstract

Introduction This study aimed to determine whether the PSI, CURB-65, CALL and BCRSS had any superiority over each other as a prognostic determinant in patients with COVID-19. Material and Method This prospective cohort study included patients over 18 years of age that presented to the emergency department between May 12 and August 12, 2020 and had a positive COVID-19 polymerase chain reaction (PCR) test. The PSI, CURB-65, CALL and BCRS scores were calculated. SPSS version 22 was used for all statistical analyses. Results A total of 213 patients with a positive COVID-19 PCR result were included in the study. The total 30-day mortality rate was determined as 14.08%. PSI, CURB-65, CALL and BCRSS had a statistically significant relationship with mortality (p<0.001). The best parameter in predicting mortality was determined as PSI (area under the curve: 0.900; 95% CI: 0.972-0.828). A positive correlation was found between each scoring system, both with the length of hospital stay (PSI, CURB-65, CALL and BCRSS: r=0.696, p=0; r=0.621, p=0; r=0.75, p=0; and r=0.666, p=0, respectively). Conclusion Scoring systems, which include comorbidity, vital signs as well as laboratory, imaging findings, will be more effective than other scoring systems in determining the mortality in patients with covid-19.

🔖

Bu Makaleye Atıf Yap

Akça, H. Ş., Algın, A., Özdemir, S., Sevimli, H., Kokulu, K., Eroğlu, S. E. (2021). Comparison of the efficacy of PSI, CURB-65, CALL and BCRSS in predicting prognosis and mortality in COVID-19 patients. Journal of Experimental and Clinical Medicine, Volume: 38 Issue: 4. https://ajindex.com/articles/1423167

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (18)

  1. Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax 2007;62(3):253-9. Doi: 10.1136/thx.2006.067371.
  2. Clinical management of COVID-19. 2020 (Updated 2020 mar 11; cited 2021 Feb 16). Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19.
  3. Duca A, Piva S, Foca E, Latronico N, Rizzi M. Calculated Decisions: Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm.)=6. Emerg Med Pract 2020;16:22(5 Suppl):CD1-CD2.
  4. Fan G, Tu C, Zhou F, Liu Z, Wang Y, Song B et al. Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. European Respiratory Journal 2020;56:2002113. Doi: 10.1183/13993003.02113-2020.
  5. Garcia Clemente MM, Huertas JH, Fernandez AF, Escosura Munoz C, Enriquez Rodriguez AI, Martinez LP et al. Assessment of risk scores in Covid 19. Int. J. Clin. Pract2020;00:e13705. https://doi.org/10.1111/ijcp.13705.
  6. Grifoni E, Valoriani A, Cei F, Vannucchi V, Moroni F, Pelagatti L et al. The CALL score for predicting outcomes in patients with COVID-19. Clin Infect Dis 2020. Doi:10.1093/cid/ciaa686.
  7. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P et al. Prediction for Progression Risk in Patients With COVID19 Pneumonia: The CALL Score. Clinical Infectious disaeses 2020;71(6):1393-9. Doi: 10.1093/cid/ciaa414.
  8. Kamran S M, Mirza Z, Moeed H, Naseem A, Hussain M, Fazal Sr I et al. CALL Score and RAS Score as Predictive Models for Coronavirus Disease 2019. Cureus 2020;12(11):e11368. Doi:10.7759/cureus.11368.
  9. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82. Lombardy Section Italian Society Infectious And Tropical Diseases. Vademecum for the treatment of people with COVID 19. Edition 2.0, 13 March 2020. Infez Med 2020;28(2):143-52.
  10. Menéndez R, Martinez R, Reyes S, Mensa J, Filella X, Marcos MA et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009;64:587-91. Doi:10.1136/thx.2008.105312.
  11. Moreno-Pérez O, Andres M, Leon-Ramirez J-M, Sánchez-Payá J, Rodríguez JC, Sánchez R et al. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study, Journal of Autoimmunity 2020;114:102523. https://doi.org/10.1016/j.jaut.2020.102523.
  12. Republic of Turkey Ministry of Health. Covid-19 Information page. 2020 (Updated 2020 mar 11; cited 2021 Feb 16). Available from: https://covid19bilgi.-saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf.
  13. Rodriguez-Nava G, Yanez-Bello MA, Trelles-Garcia DP, Chung CW, Friedman HJ, Hines DW. Performance of the quick COVID-19 severity index and the Brescia-COVID respiratory severity scale in hospitalized patients with COVID-19 in a community hospital setting. International Journal of Infectious Diseases 2021;102: 571-6. https://doi.org/10.1016/j.ijid.2020.11.003.
  14. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmunity Reviews 2020;19( 7):102568. https://doi.org/10.1016/j.autrev.2020.102568.
  15. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H et al.Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-481.
  16. Zhang C, Qin L, Li K, Wang Q, Zhao Y, Xu B et al. A novel scoring system for prediction of disease severity in COVID-19. Front Cell Infect Microbiol 2020;10:318. Doi:10.3389/fcimb.2020.00318.
  17. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62. Doi:10.1016/S0140-6736(20)30566-3.
  18. Zhu JS, Ge P, Jiang C, Zhang Y, Li X, Zhao Z et al. Deep learning artificial intelligence analysis of clinical variables predicts mortality in COVID 19 patients. Infectious Disease. JACEP Open 2020;1:1364-73. https://doi.org/10.1002/emp2.12205.